Hot Topics in Thyroid Cancer

In this video interview, Naifa Lamki Busaidy, MD, FACP, FACE, professor in the department of endocrine neoplasia and hormonal disorders, division of internal medicine at The University of Texas MD Anderson Cancer Center, discussed approved treatments and recent developments in treatment for anaplastic thyroid cancer, the importance of a multidisciplinary approach to treatment, the impact of recent FDA approvals, and current expectations regarding outcomes.

In this video, Busaidy discusses:

• The latest developments in treatments for anaplastic thyroid cancer;
• The recent FDA approval of the combination of dabrafenib mesylate and trametinib for patients with BRAF mutation;
• The importance of an aggressive treatment approach; and
• Current outcome expectations.